Drug Trial Radar · NCT06862219
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jun 21, 2025
Primary completion
Dec 31, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Mar 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is for Indian adults in India who have cancer in the bladder lining (urothelial cancer). Their cancer is advanced or has spread to other parts of the body. Enfortumab vedotin is a treatment for this type of cancer. The main aim of the study is to confirm the safety of enfortumab vedotin in Indian adults with urothelial cancer. During the study, people will receive enfortumab vedotin. The study treatment will be given to people slowly through a tube into a vein. This is called an infusion. People will receive 3 separate infusions of enfortumab vedotin in each 28-day (4 weeks) treatment cycle. People visit their study clinic for health-checks several times during and after they receive enfortumab vedotin.
Conditions
- Metastatic Urothelial Carcinoma
Interventions
Enfortumab VedotinDrug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse eventsTime frame: Up to 8 months
- Number of participants with laboratory value abnormalities and/or AEsTime frame: Up to 7 months
- Number of participants with vital sign abnormalities and/or AEsTime frame: Up to 7 months
- Number of participants with electrocardiogram (ECG) abnormalities and/or AEsTime frame: Up to 6.5 months
- Number of Participants at each grade of Eastern Cooperative Oncology Group (ECOG) Performance Status scoreTime frame: Up to 7 months
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Site IN91012
Ahmedabad, India · Recruiting
Site IN91010
Bhubaneswar, India · Recruiting
Site IN91018
Delhi, India · Recruiting
Site IN91021
Delhi, India · Recruiting
Site IN91008
Mumbai, India · Recruiting
Site IN91009
Nagpur, India · Recruiting
Site IN91001
Surat, India · Recruiting
Site IN91013
Patna, Bihar, India · Recruiting
Site IN91015
Kochi, Kerala, India · Recruiting
Site IN91004
Mumbai, Maharashtra, India · Recruiting
Site IN91016
New Delhi, National Capital Territory of Delhi, India · Recruiting
Site IN91017
Dumas, Surat, India · Recruiting
Site IN91007
Vellore, Tamil Nadu, India · Recruiting
Site IN91005
Varanasi, Uttar Pradesh, India · Recruiting
Site IN91006
Kolkata, West Bengal, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.